Repository logo
 

Complementary Activity of ETV5, RBPJ, and TCF3 Drives Formative Transition from Naive Pluripotency.

Accepted version
Peer-reviewed

Loading...
Thumbnail Image

Type

Article

Change log

Authors

Kalkan, Tüzer 
Bornelöv, Susanne 
Diamanti, Evangelia 
Lohoff, Tim 

Abstract

The gene regulatory network (GRN) of naive mouse embryonic stem cells (ESCs) must be reconfigured to enable lineage commitment. TCF3 sanctions rewiring by suppressing components of the ESC transcription factor circuitry. However, TCF3 depletion only delays and does not prevent transition to formative pluripotency. Here, we delineate additional contributions of the ETS-family transcription factor ETV5 and the repressor RBPJ. In response to ERK signaling, ETV5 switches activity from supporting self-renewal and undergoes genome relocation linked to commissioning of enhancers activated in formative epiblast. Independent upregulation of RBPJ prevents re-expression of potent naive factors, TBX3 and NANOG, to secure exit from the naive state. Triple deletion of Etv5, Rbpj, and Tcf3 disables ESCs, such that they remain largely undifferentiated and locked in self-renewal, even in the presence of differentiation stimuli. Thus, genetic elimination of three complementary drivers of network transition stalls developmental progression, emulating environmental insulation by small-molecule inhibitors.

Description

Keywords

ETS factors, RBPJ, commitment, differentiation, embryonic stem cell, epiblast, gene regulatory network, pluripotency, self-renewal, Animals, Basic Helix-Loop-Helix Transcription Factors, Cell Differentiation, Cell Line, Cell Lineage, Cell Self Renewal, DNA-Binding Proteins, Gene Knockout Techniques, Gene Regulatory Networks, Immunoglobulin J Recombination Signal Sequence-Binding Protein, Mice, Mice, Inbred C57BL, Mice, Inbred CBA, Nanog Homeobox Protein, Neurons, Pluripotent Stem Cells, RNA, Small Interfering, T-Box Domain Proteins, Transcription Factors

Journal Title

Cell Stem Cell

Conference Name

Journal ISSN

1934-5909
1875-9777

Volume Title

24

Publisher

Elsevier BV
Sponsorship
European Commission (200720)
Wellcome Trust (097922/Z/11/Z)
Medical Research Council (MR/P00072X/1)
Biotechnology and Biological Sciences Research Council (BB/M004023/1)
This research was funded by the Wellcome Trust, the Biotechnology and Biological Sciences Research Council, European Commission (contract no. 200720, EuroSyStem) and the Louis Jeantet Foundation. The Cambridge Stem Cell Institute receives core support from the Wellcome Trust and the Medical Research Council. AS is a Medical Research Council Professor.